Sanjeev Redkar PHD, MBA


Dr. Sanjeev Redkar is the President & Co-Founder of Apollomics Inc., a biotech company developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways. In his previous role, Dr. Redkar was Senior Vice President of Product Development at Astex Pharmaceuticals, an Otsuka company. Dr. Redkar has led the development of several oncology therapeutics though Investigational New Drug (IND) applications and global launches including Dacogen, Nipent and Mitozytrex. Additionally, Dr. Redkar worked on multiple drugs through their FIH submission and clinical trials that led to the buyout of Astex to Otsuka for close to a billion dollars. He has over 25 years of oncology drug-development experience, over 25 peer-reviewed publications and 150 patents. Dr. Redkar earned his Ph.D. from University of Colorado, an MBA from St. Mary’s College of California, and a Bachelor’s from the Indian Institute of Technology, Bombay. Dr. Redkar is an Adjunct faculty and a Board Member at the University of the Pacific School of Pharmacy, Stockton, and Advisory Board of University of Colorado, Boulder, Chemical Engineering Department.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of oncology therapies that harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of six development-stage assets including: three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells; and three targeted therapies against uncontrolled growth signaling pathways.